Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $18.6 million.

  • Zhengye Biotechnology Holding's Total Current Liabilities changed N/A to $18.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $18.6 million, marking a year-over-year change of. This contributed to the annual value of $18.9 million for FY2024, which is 1102.67% down from last year.
  • Zhengye Biotechnology Holding's Total Current Liabilities amounted to $18.6 million in Q2 2025.
  • Over the past 5 years, Zhengye Biotechnology Holding's Total Current Liabilities peaked at $20.9 million during Q4 2023, and registered a low of $18.6 million during Q2 2025.
  • Its 3-year average for Total Current Liabilities is $19.5 million, with a median of $18.9 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Zhengye Biotechnology Holding's Total Current Liabilities was 932.2% (2024), while the steepest drop was 932.2% (2024).
  • Quarter analysis of 3 years shows Zhengye Biotechnology Holding's Total Current Liabilities stood at $20.9 million in 2023, then dropped by 9.32% to $18.9 million in 2024, then fell by 1.48% to $18.6 million in 2025.
  • Its last three reported values are $18.6 million in Q2 2025, $18.9 million for Q4 2024, and $20.9 million during Q4 2023.